Information Provided By: 
Fly News Breaks for December 13, 2016
OPHT, OHRP
Dec 13, 2016 | 07:16 EDT
H.C. Wainwright analyst Corey Davis believes Ophthotech's (OPHT) wet AMD failure is not a "completely negative read-through" for Ohr Pharmaceutical's (OHRP) squalamine. Ohr has changed more in going from Phase 2 to Phase 3 than Ophthotech did, Davis tells investors in a research note. Further, there are several mechanistic differentiators as Ohr excludes patients with "occult" lesions larger than 10mm2, the analyst adds. Davis keeps a Buy rating on Ohr with a $10 price target.
News For OHRP;OPHT From the Last 2 Days
There are no results for your query OHRP;OPHT
